Literature DB >> 234031

Microsomal metabolism of nitrosoureas.

D L Hill, M C Kirk, R F Struck.   

Abstract

N, N-Bis (2-chloroethyl)-N-nitrosourea (BCNU) is a substrate for a microsomal enzyme of mouse liver. The reaction requires NADPH, and the product is 1, 3-bis (2-chloroethyl) urea. This activity is also found in mouse lungs but not in several other tissues. With reaction conditions under which BCNU is not chemically degraded, the Km for BCNU with liver microsomes is 1.7 mM; nicotine is a competitive inhibitor with a Ki of 0.6 mM. N-Methyl-N-nitrosourea is denitrosated in a similar reaction. N- (2-Chloroetyhy)- N-cyclohexyl-N-nitrosourea and N-(2-chloroethyl)-N-(trans-4-methylcyclohexyl)-N-nitrosourea are also substrates for microsomal enzymes, but the products of these reactions are ring-hydroxylated derivatives. The Km value for N-(2-CHLOROETHYL)-N-cyclohexyl-N-nitrosourea is 3.0 mM and that for N-(2-chloroethyl)-N-(trans-4-methylcyclohexyl)-N-nitrosourea is 1.0 mM. The hydroxylase activity is also present in lungs, but not in the other mouse tissues. The rates of microsomal metabolism of BCNU, N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea, and N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea, and N-(2-chloroethyl-N-(trans-4-methylcyclohexyl)-N-nitrosourea are fast enough to allow metabolism of large portions of administered doses before chemical decomposition of the drugs occurs.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 234031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.

Authors:  L Papavero; F Loew; H Jaksche
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

Review 2.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 3.  Intestinal and liver toxicity of antineoplastic drugs.

Authors:  G B McDonald; N Tirumali
Journal:  West J Med       Date:  1984-02

4.  Pharmacokinetics of 11C-BCNU in experimental brain tumor.

Authors:  K Sako; M Diksic; S Farrokhzad; Y L Yamamoto; W Feindel
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

Review 5.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.

Authors:  B Drewinko; L Y Yang
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

7.  Capillary gas chromatography and thermionic N-P-specific detection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in stability and pharmacokinetic studies.

Authors:  A El-Yazigi; C R Martin
Journal:  Pharm Res       Date:  1988-04       Impact factor: 4.200

8.  BCNU-induced quantitative and qualitative changes in hepatic cytochrome P-450 can be correlated with cholestasis.

Authors:  J C Stolzenbach; R E Larson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.

Authors:  B C Liang
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

10.  Distribution of 13N in rat tissues following intravenous administration of nitroso-labeled BCNU.

Authors:  B R Freed; R L McQuinn; R S Tilbury; G A Digenis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.